Trexima NDA Filing Relieves Pozen’s MT 100 Headache
This article was originally published in The Pink Sheet Daily
Executive Summary
Acceptance of the NDA filing will trigger a $20 mil. milestone payment from GlaxoSmithKline.
You may also be interested in...
Trexima Approvable Letter Another Headache For Pozen
Pozen and GlaxoSmithKline had been seeking a third quarter launch.
Trexima Approvable Letter Another Headache For Pozen
Pozen and GlaxoSmithKline had been seeking a third quarter launch.
Endo/Vernalis Seek Menstrual Migraine Indication For Frova
sNDA will be filed with FDA in the coming weeks following positive Phase III trial results.